<?xml version="1.0" encoding="UTF-8"?>
<p id="Par59">The primary endpoint of this study is the rate of ongoing response according to RECIST v1.1 [
 <xref ref-type="bibr" rid="CR34">34</xref>] at 24Â months (from first start of treatment with PD-1 blockade).
</p>
